OL

Oriella Ltd.

Description

Oriella Ltd. is a prominent private equity and technology investor.

Investor Profile

Oriella Ltd. has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series Unknown (67%)
  • Series B (33%)

Country Focus

  • Israel (100%)

Industry Focus

  • Biotechnology
  • Medical
  • Pharmaceutical
  • Food And Beverage
  • Manufacturing
  • Waste Management
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Oriella Ltd. frequently co-invest with?

Shavit Capital
Asia, Yerushalayim, Israel, Jerusalem
Co-Investments: 1
Peregrine Ventures
Asia, Tel Aviv, Israel, Or Yehuda
Co-Investments: 1
CF
North America, Louisiana, United States, Shreveport
Co-Investments: 1
Dafna Capital Management
North America, California, United States, Los Angeles
Co-Investments: 1
Mirae Asset Venture Investment
Asia, Kyonggi-do, South Korea, Seongnam
Co-Investments: 2
aMoon Fund
Asia, HaMerkaz, Israel, Ra'anana
Co-Investments: 1
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 1
HBL Hadasit Bio Holdings
Asia, Yerushalayim, Israel, Jerusalem
Co-Investments: 2
Flerie Invest
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 2
Pavilion Capital
North America, New York, United States, New York
Co-Investments: 2

Which angels does Oriella Ltd. often collaborate with?

Tal Shapira
Asia, Israel
Shared Deals: 1
Eddy Shalev
Asia, Israel
Shared Deals: 1

What are some of recent deals done by Oriella Ltd.?

TripleW Ltd.

Netanya, HaMerkaz, Israel

TripleW upcycles food waste into high-demand, high-value lactic acid, the building block of PLA bioplastics.

BiotechnologyFood and BeverageManufacturingWaste Management
Series BMar 1, 2023
Amount Raised: $16,500,000
KAHR medical

Jerusalem, Yerushalayim, Israel

KAHR Medical develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases.

BiotechnologyMedicalPharmaceutical
Series UnknownJun 16, 2021
Amount Raised: $46,500,000
KAHR medical

Jerusalem, Yerushalayim, Israel

KAHR Medical develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases.

BiotechnologyMedicalPharmaceutical
Series UnknownFeb 25, 2020
Amount Raised: $18,000,000